Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30453036 | 0.89 | CNR1 (0.49) | METALKMAP4K3PIK3CAEPHX2 | |
| SCHEMBL488395 | 0.89 | CNR1 (0.49) | METALKMAP4K3PIK3CAEPHX2 | |
| SCHEMBL487851 | 0.84 | MET (0.49) | METALKMAP4K3 | |
| SCHEMBL30453593 | 0.84 | MET (0.49) | METALKMAP4K3 | |
| SCHEMBL30454107 | 0.84 | MET (0.59) | METALK | |
| SCHEMBL488600 | 0.84 | MET (0.59) | METALK | |
| SCHEMBL488088 | 0.83 | ALK (0.54) | METALKMAP4K3 | |
| SCHEMBL488697 | 0.82 | MET (0.55) | METMAP4K3EPHX2 | |
| SCHEMBL30453380 | 0.82 | MET (0.55) | METMAP4K3EPHX2 | |
| SCHEMBL488801 | 0.81 | MET (0.55) | METALKMAP4K3PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | MET 1/4885ALK 138/4885MAP4K3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.